Pfizer, Inc. (PFE) Shares Sold by DF Dent & Co. Inc.

DF Dent & Co. Inc. lowered its position in shares of Pfizer, Inc. (NYSE:PFE) by 4.3% during the first quarter, Holdings Channel reports. The institutional investor owned 30,818 shares of the biopharmaceutical company’s stock after selling 1,384 shares during the period. DF Dent & Co. Inc.’s holdings in Pfizer were worth $1,054,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its position in Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after buying an additional 377,404 shares in the last quarter. Brown Advisory Securities LLC raised its position in Pfizer by 6.8% in the first quarter. Brown Advisory Securities LLC now owns 60,015 shares of the biopharmaceutical company’s stock worth $2,054,000 after buying an additional 3,825 shares in the last quarter. Good Life Advisors LLC raised its position in Pfizer by 24.7% in the first quarter. Good Life Advisors LLC now owns 18,348 shares of the biopharmaceutical company’s stock worth $624,000 after buying an additional 3,629 shares in the last quarter. Comerica Securities Inc. raised its position in Pfizer by 33.0% in the first quarter. Comerica Securities Inc. now owns 23,985 shares of the biopharmaceutical company’s stock worth $821,000 after buying an additional 5,947 shares in the last quarter. Finally, Argent Capital Management LLC raised its position in Pfizer by 0.9% in the first quarter. Argent Capital Management LLC now owns 669,575 shares of the biopharmaceutical company’s stock worth $22,906,000 after buying an additional 6,076 shares in the last quarter. Institutional investors and hedge funds own 70.10% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.21% during trading on Thursday, reaching $33.38. 2,725,487 shares of the company were exchanged. The firm has a 50-day moving average of $33.44 and a 200-day moving average of $33.30. The firm has a market cap of $199.21 billion, a price-to-earnings ratio of 24.42 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.53.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is presently 94.12%.

TRADEMARK VIOLATION NOTICE: This article was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/2799120/pfizer-inc-pfe-shares-sold-by-df-dent-co-inc.html.

A number of research firms recently commented on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Finally, UBS AG reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $37.77.

In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.